AFMD - Here's Why Shares of Affimed Skyrocketed Today
Shares of drugmaker Affimed (NASDAQ: AFMD) are up 19% at 2:06 p.m. EDT after the company disclosed positive data from an early-stage clinical trial of its innate cell engager AFM13 in patients with Hodgkin's lymphoma.
The data release only included results from the first four patients in the study, but they were impressive nonetheless.
All four patients responded to the therapy, which included giving the patients immune cells called natural killer (NK) cells and AFM13 that attracts the NK cells to the tumor cells. Two patients had a complete response, while the other two had a partial response. Adding to the impressiveness, these patients had already failed between four and 14 different lines of therapy before being given the NK cells plus AFM13.
For further details see:
Here's Why Shares of Affimed Skyrocketed Today